GSK’s Malaria Drug Tafenoquine Heads To US FDA Panel Review With Agency Backing

Approval could bring GlaxoSmithKline a tropical disease priority review voucher.

Malaria Cells_321361517_1200.jpg
US FDA advisors will consider whether there is substantial evidence of effectiveness for tafenoquine as a radical cure for Plasmodium vivax malaria.

The US FDA is bringing GlaxoSmithKline PLC’s single-dose malaria drug Krintafel (tafenoquine) to a July 12 advisory committee meeting despite apparently having no major concerns about the adequacy of the efficacy and safety data to support approval.

In separate voting questions, the agency asks its Antimicrobial Drugs Advisory Committee whether GSK has provided substantial evidence of effectiveness...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers